Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

Clinical trial NCT04837651 · COMPLETED

Trial details

NCT number: NCT04837651
Sponsor: Dragonfly Research, LLC
Status: COMPLETED
Study type: OBSERVATIONAL

Multiple Sclerosis Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Pathologic Processes

Start date: 2021-03-02
Primary completion: 2021-07-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.